Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

← catalyst calendar

NCT05489705 · readout in 1,094 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
1,700estimated
Sites
101
Countries
Austria, Czechia, France +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-08-16actualWhen the study began enrolling
Primary completion2029-08-17estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-08-17estimatedThe whole study's end, after follow-up
First posted2022-08-05actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Obstructive Hypertrophic Cardiomyopathy

Interventions

  • Drug: Mavacamten
  • Drug: Non-mavacamten symptomatic oHCM therapy

Primary outcomes

what the primary-completion date above is the date OF
Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment
measured Up to 5 Years
Change in resting left ventricular outflow tract (LVOT) gradient from baseline
measured Up to 18 months

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed